Last reviewed · How we verify

NCT05250414

Single-Sided Deafness in the Medicare Population

Completed NA Last updated 29 September 2025
What this trial tests

NA trial testing MED-EL Cochlear Implant System in Hearing Loss, Unilateral in 15 participants. Completed in 11 August 2025.

Timeline
27 June 2022
Primary endpoint
11 August 2025
11 August 2025

Quick facts

Lead sponsorMed-El Corporation
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment15
Start date27 June 2022
Primary completion11 August 2025
Estimated completion11 August 2025
Sites3 locations across Canada, United States

Drugs / interventions tested

Conditions studied

Sponsor

Med-El Corporation — full company profile →

Who can join

65 and older, any sex, with Hearing Loss, Unilateral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and effectiveness of cochlear implantation in adults 65 years of age and older.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Improvements in Perceived Abilities and Speech Recognition in Quiet and Noise for Older Adults With Single-sided Deafness or Asymmetric Hearing Loss: A Multi-center Investigation.
    Dillon MT, Smilsky K, Dunn CC, Sheets JJ, et al · · 2026 · cited 1× · PMID 41094701 · DOI 10.1097/mao.0000000000004667

Verify or expand the search:

Other recruiting trials for Hearing Loss, Unilateral

Currently open trials in the same condition.

Other Med-El Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05250414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing